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Influence of traumatic brain injury 
on extracellular tau elimination at the blood–
brain barrier
Maxwell Eisenbaum1,2* , Andrew Pearson1,2, Arissa Gratkowski1, Benoit Mouzon1,2,3, Michael Mullan1,2, 
Fiona Crawford1,2,3, Joseph Ojo1,2 and Corbin Bachmeier1,2,4 
Abstract 
Repetitive head trauma has been associated with the accumulation of tau species in the brain. Our prior work showed 
brain vascular mural cells contribute to tau processing in the brain, and that these cells progressively degenerate 
following repetitive mild traumatic brain injury (r-mTBI). The current studies investigated the role of the cerebrovascu-
lature in the elimination of extracellular tau from the brain, and the influence of r-mTBI on these processes. Following 
intracranial injection of biotin-labeled tau, the levels of exogenous labeled tau residing in the brain were elevated 
in a mouse model of r-mTBI at 12 months post-injury compared to r-sham mice, indicating reduced tau elimina-
tion from the brain following head trauma. This may be the result of decreased caveolin-1 mediated tau efflux at the 
blood–brain barrier (BBB), as the caveolin inhibitor, methyl-β-cyclodextrin, significantly reduced tau uptake in isolated 
cerebrovessels and significantly decreased the basolateral-to-apical transit of tau across an in vitro model of the BBB. 
Moreover, we found that the upstream regulator of endothelial caveolin-1, Mfsd2a, was elevated in r-mTBI cer-
ebrovessels compared to r-sham, which coincided with a decreased expression of cerebrovascular caveolin-1 in the 
chronic phase following r-mTBI (> 3 months post-injury). Lastly, angiopoietin-1, a mural cell-derived protein govern-
ing endothelial Mfsd2a expression, was secreted from r-mTBI cerebrovessels to a greater extent than r-sham animals. 
Altogether, in the chronic phase post-injury, release of angiopoietin-1 from degenerating mural cells downregulates 
caveolin-1 expression in brain endothelia, resulting in decreased tau elimination across the BBB, which may describe 
the accumulation of tau species in the brain following head trauma.
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Introduction
Exposure to repetitive head injuries sustained in the 
military or contact sports has been associated with 
an increased risk for the development of chronic neu-
rodegenerative diseases, including chronic traumatic 
encephalopathy (CTE) [34]. Though the underlying 
mechanism behind the progression of CTE is unclear, 
the neuropathologic presentation has become appar-
ent through postmortem examination. CTE appears 
to be a primary tauopathy characterized, in part, by a 
perivascular accumulation of pathological hyperphos-
phorylated tau at the depths of cortical sulci [35]. Tau, 
which primarily supports the functions of microtu-
bules in neurons, has traditionally been viewed as an 
intracellular protein, but recent research has revealed 
an important pathological role of extracellular tau in 
neurodegenerative progression [36]. Furthermore, 
traumatic brain injury (TBI) results in elevated levels 
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of extracellular tau in the interstitial fluid (ISF) of the 
central nervous system (CNS) [33], which has been cor-
related with adverse clinical outcomes [32, 46].
Though extracellular tau has an important role in dis-
ease pathogenesis, the mechanisms by which extracel-
lular tau is eliminated from the brain and the influence 
of TBI on these processes has been largely unexplored. 
While extracellular solutes can be eliminated from the 
brain through bulk flow or perivascular pathways, a 
major route of elimination occurs via transit across the 
blood–brain barrier (BBB). Microdialysis studies investi-
gating tau movement in brain interstitial fluids have sug-
gested tau may be more dynamically linked to the blood 
than the cerebrospinal fluid [57, 59], implicating possible 
interactions with the BBB. Several pathogenic proteins 
have been shown to cross the BBB [7, 13, 53], includ-
ing tau [8], but the processes driving BBB tau transit 
are not fully understood, particularly following trauma 
to the brain. It has been suggested that degradation and 
perivascular clearance may be responsible for a greater 
magnitude of extracellular tau elimination than bulk flow 
to the CSF [59].
Our recent work found brain vascular mural cells 
progressively degenerate at chronic time points follow-
ing repetitive mild traumatic brain injury (r-mTBI) in a 
mouse model of concussion [45]. Moreover, these effects 
were associated with reduced cerebrovascular tau uptake 
in freshly isolated cerebrovessels from r-mTBI animals. 
Notably, the decrease in tau uptake post-injury coincided 
with significant reductions in cerebrovascular caveo-
lin-1 levels in the mouse r-mTBI model. Caveolin-1 is 
an integral membrane component for the formation and 
function of caveolae-mediated cerebrovascular transcy-
tosis. Additionally, our prior studies observed decreased 
caveolin-1 expression in cerebrovessels from human TBI 
brain specimens when compared to non-injured control 
brains [45]. While few studies have investigated the rela-
tionship between tau and cerebrovascular caveolin-1, it 
has been reported that mice with decreased caveolin-1 
expression exhibit elevated levels of total and phos-
phorylated tau in the brain [10, 25]. Caveolin-1 activity 
in brain endothelial cells is primarily regulated by the 
lysolipid transporter Mfsd2a (major facilitator superfam-
ily domain‐containing protein‐2a) [2, 9]. Mfsd2a plays a 
critical role in maintaining BBB permeability, and it was 
found that overexpression of Mfsd2a after brain injury 
can be neuroprotective [63]. While it has been observed 
that Mfsd2a levels downregulate in the acute phase fol-
lowing brain injury [16, 17], the state of cerebrovascular 
Mfsd2a at more chronic stages post-injury have not been 
investigated, not to mention the resulting effect on cave-
olin-1 levels and tau elimination across the BBB. The goal 
of this study is to investigate the mechanisms influencing 
tau elimination at the BBB and determine the chronic 
effects of repetitive head trauma on these processes.
Materials and methods
Materials
Primary human brain vascular pericytes (HBVP) 
(cat#1200), primary human brain microvascular 
endothelial cells (HBMEC) (cat#1000), and associated 
culture reagents were purchased from Sciencell Research 
Laboratories (Carlsbad, CA, USA). Fibronectin solution 
(cat#F1141), poly-L-lysine solution (cat#P4707), methyl-
β-cyclodextrin (cat#C4555), Thioflavin S (cat#T1892-
25G), heparin (cat#H3393-10KU) and Hanks’ balanced 
salt solution (HBSS) (cat#H8264) were purchased from 
MilliporeSigma (St. Louis, MO, USA). Lucifer yellow dex-
tran (10 kDa) and the human tau enzyme linked immu-
nosorbent assay (ELISA) (cat#KHB0041) were purchased 
from Invitrogen Corp. (Carlsbad, CA, USA). Mamma-
lian protein extraction reagent (M-PER) (cat#78505), 
Halt enzyme inhibitor cocktails (cat#78442), Super-
Signal West Fempto Maximum Sensitivity Substrate 
(cat#PI34095), and the bicinchoninic acid (BCA) protein 
assay (cat#23225) were purchased from ThermoFisher 
Scientific (Waltham, MA, USA). The ELISA kits for 
mouse Major facilitator superfamily domain contain-
ing 2 (Mfsd2a) (cat#LS-F17827-1), and human Mfsd2a 
(cat#LS-F17826-1) were purchased from LifeSpan Bio-
Sciences, Inc. (Seattle, WA, USA). The ELISA kit for 
mouse caveolin-1 (cat#MBS721447) was purchased from 
MyBioSource, Inc. (San Diego, CA, USA). The ELISA 
kit for mouse angiopoietin-1 (Ang-1) (cat#NBP2-62857) 
was purchased from Novus Biologicals (Littleton, CO, 
USA). The ELISA kit for mouse angiopoietin-2 (Ang-
2) (cat#MANG20) was purchased from R&D Systems 
(Minneapolis, MN, USA). Recombinant human tau-441 
(rhtau) (cat#T-1001-2) was purchased from rPeptide 
(Watkinsville GA, USA). Recombinant biotin-labeled 
human tau-441 (cat#T08-54BN), and recombinant 
DYRK1A-phosphorylated and biotin-labeled human 
tau (cat#T08-50RNB) were purchased from SignalChem 
(Richmond, BC, Canada).
Animals
Both male and female mice [Human tau (hTau) (cat# 
005491) and wild-type (C57BL/6) (cat# 000664)] were 
purchased from the Jackson Laboratory (Bar Harbor, 
ME, USA). All studies used a mix of male and female 
mice. The hTau mice express six isoforms of human tau 
on a C57BL/6 background, but do not express murine 
tau, as previously described [1]. The hTau genotype 
was confirmed after purchase using PCR from a tail 
snip via a third party (Transnetyx, Cordova, TN, USA). 
In our recent work, we investigated several time points 
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following r-mTBI using the hTau animals to evaluate 
the association between mural cell dysfunction and tau 
accumulation in the brain [45]. To better align the cur-
rent studies with this previous work, we used the same 
hTau tissue samples from the prior studies to evaluate 
the chronic effect of r-mTBI on angiopoietin, Mfsd2a, 
and caveolin-1. All studies used mice housed 3 per cage 
under standard laboratory conditions (23 ± 1 ℃, 50 ± 5% 
humidity, and a 12-h light/dark cycle) with free access to 
food and water throughout the study. All experiments 
using animals were performed under protocols approved 
by the Institutional Animal Care and Use Committee 
(IACUC) of the Roskamp Institute.
Brain injury protocol
Repetitive mild traumatic brain injury (r-mTBI) was 
administered using a mouse model of closed head injury 
as previously characterized by our group [39, 40]. Briefly, 
after being 1.5 L/min of oxygen and 3% isoflurane, mice 
had their head shaved and were secured in a mouse 
stereotaxic apparatus (Stoelting) mounted with an elec-
tromagnetic controlled impact device (Leica) and a 
heating pad to maintain their body temperature. Before 
impact, a 5  mm blunt metal impactor tip was retracted 
and positioned midway in relation to the sagittal suture. 
The injury was triggered using the myNeuroLab control-
ler (Leica) at a strike velocity of 5  m/s, strike depth of 
1.0 mm, and a dwell time of 200 ms. Randomly assigned 
three-month-old mice received 2 injuries per week, 
approximately 72  h apart, for 3  months (r-mTBI). As a 
control, sham animals did not receive the brain injury, 
but were exposed to anesthesia for the same length of 
time as the injured mice and under the same paradigm 
(2 exposures per week for 3 months). Mice (hTau) were 
euthanatized at 24 h, 3 months, 6 months after the final 
brain injury or anesthesia exposure. The sample sizes for 
the r-sham and r-mTBI groups were the same for each 
post-injury time point: 24 h (n = 4), 3 months (n = 7), and 
6 months (n = 11). For the intracranial tau injection stud-
ies, mice (wild-type) were euthanized at 12 months after 
the final brain injury. The sample sizes for the r-sham 
and r-mTBI groups in the intracranial tau injection study 
were n = 4–8 for each tau species.
Isolation of brain fractions
The cerebrovasculature was isolated from mouse tissue 
as characterized and described by our group previously 
[4]. Briefly, fresh mouse cortices were ground in 5  ml 
of ice-cold HBSS with 6–8 passes of a Teflon pestle in a 
glass Dounce homogenizer. A 250 μl aliquot of homogen-
ate was collected with lysis buffer (M-PER) supplemented 
with phenylmethanesulfonyl fluoride (1  mM) and Halt 
protease and phosphatase inhibitor cocktail. An equal 
volume of 40% dextran solution was added to the remain-
ing brain homogenate for a final concentration of 20% 
dextran and immediately centrifuged at 6000 g for 15 min 
at 4˚C. This procedure results in a pellet at the bottom of 
the container (cerebrovasculature) and a compact mass at 
the top of the solution (parenchyma) separated by a clear 
dextran interface (soluble fraction, i.e., non-cell associ-
ated). The freshly isolated vessels were collected and 
immediately used for the ex vivo studies described below.
Tau aggregation
Enriched fractions of low molecular weight aggregated 
tau were generated as previously described [37]. Briefly, 
biotin-labeled tau (4.35  µM) was incubated with freshly 
prepared heparin (1  µM) for 6  h at 37  °C. To moni-
tor aggregation activity, monomeric biotin-labeled tau 
(4.35 µM) was incubated with or without heparin (1 µM) 
in the presence of the aggregation indicator dye, Thiofla-
vin S (ThS) (20 µM). ThS fluorescence (excitation 450 nm, 
emission 510), was analyzed at baseline (0 h) and at 6 h 
for each group using a microplate spectrofluorometer 
(Biotek Cytation 3), to determine the change in relative 
fluorescence units. After confirmation of aggregation, 
the aggregate enriched solution of biotin-labeled tau was 
passed through a 100  kDa MWCO filter (Corning) and 
centrifuged at 14,000 × g for 25 min at 4 °C. The concen-
trated, aggregate enriched fraction (MW > 100 kDa) was 
collected and stored at −  80  °C. The filtered fraction of 
seed competent monomers and dimers (MW < 100 kDa) 
were subsequently concentrated using a 30 kDa MWCO 
filter (Corning) and centrifuged at 14,000 × g for 25 min 
at 4 °C. The final protein concentrations were determined 
using a biotin-labeled tau ELISA. Misfolding of the seed 
competent monomeric fraction was confirmed using dot 
blot. Concentration (50 ng/ml) matched aliquots (1 μl) of 
monomeric biotin-labeled tau, seed competent biotin-
labeled tau, and aggregate enriched biotin-labeled tau, 
were placed on a nitrocellulose membrane for 30  min 
at room temperature before blocking in 10% BSA in tris 
buffered saline with 0.1% Tween-20 (TBS-T) overnight 
at 4  °C. The membrane was incubated for 1  h in MC1 
(MC1, 1:1000 diluted in TBS-T with 5% BSA), vigorously 
washed with TBS-T, then incubated in horseradish per-
oxidase-conjugated anti-mouse secondary antibody (goat 
anti-mouse IgG 1:1000 in TBS-T with 5% BSA) for 1  h 
at room temperature. After an additional wash in TBS-
T, SuperSignal West Femto Maximum Sensitive Substate 
(ThermoFisher) was used for chemiluminescence detec-
tion and signal intensity ratios were quantified with the 
ChemiDoc TM XRS (Bio-Rad). MC1 is a conformation-
dependent tau antibody raised against paired helical fila-
ment tau from Alzheimer’s disease brain homogenate, 
whose reactivity depends on the N terminus (amino acids 
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7–9) and the C-terminus (amino acids 313–322) [27], and 
was generously provided by Dr. Peter Davies, The Fein-
stein Institute for Medical Research, Bronx, NY, USA.
Tau elimination
For the temporal tau elimination studies, 6 wild-type 
mice (9  months of age) were anesthetized via inhala-
tion using a 3% isoflurane/oxygen mix and maintained 
at 37 °C using a homeothermic blanket. mice were stere-
otaxically injected into the brain with (50 μg/ml) human 
biotin-labeled tau in 3 μl of PBS (0.5 mm anterior to the 
bregma, 2  mm lateral to the midline, and 3  mm below 
the surface of the skull) as per our prior methods [47]. 
In a separate cohort of mice, 10 kDa lucifer yellow dex-
tran (LyD) (100 mg/ml) was stereotaxically injected into 
the brain in the same manner as above, to provide con-
text for the tau studies, as LyD does not readily cross 
the BBB [42]. Mice were euthanized at 10  min, 30  min, 
1, 2, 4, 8, and 24  h after the intracranial injection. The 
brain was harvested, and each hemisphere was homog-
enized with probe sonication in 500 μl of lysis buffer. The 
half-life for both biotin-labeled tau and LyD was deter-
mined using nonlinear regression and a one phase decay 
fit (GraphPad Prism 8.0, GraphPad Software, Inc) using 
the following equation: Y = (Y0  −  Plateau) * exp (-K * 
X) + Plateau. Y0 is the Y value when X (time) is zero and 
the Plateau is the Y value at infinite times, both of which 
are expressed in the same units as Y. K is the rate con-
stant, expressed in reciprocal of the X axis time units. If 
X is in minutes, then K is expressed in inverse minutes. 
Tau is the time constant, expressed in the same units as 
the X axis. It is computed as the reciprocal of K. The half-
life is in the time units of the X axis. It is computed as 
ln(2)/K. Lastly, the span is the difference between Y0 and 
Plateau, expressed in the same units as the Y values [38]. 
The value at time = 0 (y-intercept) was used as the theo-
retical initial concentration in the brain and the values at 
each time point were calculated as a percentage of this 
initial concentration.
Tau residence in the brain
Biotin-labeled tau species and 10  kDa lucifer yellow 
dextran (LyD) were stereotaxically injected into r-sham 
and r-mTBI wild-type mice (12  months post-injury), 
in the same manner as the temporal studies above, and 
euthanatized 2  h after the intracranial injection. The 
brain homogenate was evaluated for biotin-labeled tau 
using a modified hTau ELISA (Invitrogen). The ELISA 
was performed according to the manufacturer’s protocol, 
using stock biotin-labeled tau as the standard and exclud-
ing the 1-h incubation step with a biotin-conjugated pri-
mary antibody. Furthermore, each stereotaxic injection 
included LyD (80 mg/ml) to account for any nonspecific 
leakage out of the brain, as LyD typically demonstrates 
low BBB permeability [42]. LyD fluorescence was ana-
lyzed using a microplate spectrofluorometer (Biotek 
Cytation 3). With respect to tau, all samples were evalu-
ated for exogenous biotin-labeled tau remaining in the 
brain and normalized to LyD for each time point. To 
assess LyD alone, the amount of LyD at each time point 
was normalized to total protein content as determined 
using the BCA assay.
Caveolin‑1 and Mfsd2a expression in r‑mTBI mice
Cerebrovessels from hTau r-sham and r-mTBI mice at 
24  h, 3 and 6  months post-injury were collected using 
lysis buffer (M-PER) supplemented with phenylmeth-
anesulfonyl fluoride (1 mM) and Halt protease and phos-
phatase inhibitor cocktail. The cell lysates were analyzed 
for caveolin-1 and Mfsd2a by ELISA and normalized to 
total protein content using the BCA protein assay.
Tau uptake and caveolin inhibition ex vivo
Freshly isolated cerebrovessels from naïve wild-type 
mice (9 months of age) were pre-treated with methyl-β-
cyclodextrin (0, 1, and 10  mM) for 30  min at 37˚C fol-
lowed by treatment with 5 ng/ml rhtau for 1 h at 37 ℃. 
Following the treatment period, the extracellular media 
was removed, and the cerebrovessels were washed with 
ice-cold HBSS. Cell lysates were collected using lysis 
buffer (M-PER) supplemented with phenylmethanesulfo-
nyl fluoride (1 mM) and Halt protease and phosphatase 
inhibitor cocktail. The cell lysates were analyzed for total 
tau by ELISA and normalized to total protein content 
using the BCA protein assay.
Angiopoietin‑1 modulates HBMEC expression of Mfsd2a 
in vitro
Fully confluent HBMECs were treated with 2.5 ng/ml of 
Ang-1 or a vehicle in ECM for 24 h. Cells were washed 
with HBSS and cell lysates were collected using lysis 
buffer as described previously. The cell lysates were ana-
lyzed for Mfsd2a by ELISA and normalized to total pro-
tein content using the BCA protein assay.
Cerebrovascular angiopoietin 1/2 secretion ex vivo
Freshly isolated cerebrovessels from r-sham and r-mTBI 
mice 6  months post-injury were incubated in ECM for 
72 h at 37˚C. Following the incubation, the extracellular 
media was collected, the cerebrovessels were washed in 
ice-cold HBSS, then collected in lysis buffer as described 
previously. The extracellular media was evaluated for 
secretion of Ang-1 and Ang-2 by ELISA and normal-
ized to the corresponding cell lysate total protein content 
using the BCA protein assay.
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In vitro BBB assay
Using HBVP and HBMEC cells, a contact coculture ver-
sion of our previously characterized in vitro BBB model 
(Bachmeier 2010) was used to evaluate tau transcyto-
sis. Briefly, HBVP were seeded at 25,000 cells/cm2 onto 
the exterior portion of poly-L-lysine coated 24-well 
0.4  μm-pore membrane inserts. One hour after HBVP 
seeding, HBMEC were seeded at 50,000 cells /  cm2 onto 
the interior membrane of the fibronectin-coated insert 
to establish a polarized monolayer. The layer of cells 
separates this system into an apical (“blood” side) and 
basolateral (“brain” side) compartment. The basolateral 
compartment was exposed to monomeric or aggregated 
biotin-labeled tau (200 ng/ml) in the presence or absence 
of MβCD (10 mM), while fresh media was placed in the 
apical compartment. The inserts containing media were 
exposed to the wells containing biotin-labeled tau and 
incubated at 37  °C. The basolateral compartment was 
sampled at time 0 to establish the initial concentration of 
biotin-labeled tau. Samples were collected from the api-
cal compartment at 0, 30, and 60 min to assess the rate 
of biotin-labeled tau transcytosis across the cell mon-
olayer (basolateral-to-apical) and analyzed for biotin-
labeled tau using a modified hTau ELISA. Furthermore, 
each basolateral compartment was exposed to a known 
paracellular marker, 10  kDa lucifer yellow dextran (LyD 
10 µM), to monitor cellular integrity and/or nonspecific 
permeability, as we previously described [5]. The appar-
ent permeability (Papp) was determined using the equa-
tion Papp = 1/AC0 * (dQ / dt), where A represents the 
surface area of the membrane, C0 is the initial concentra-
tion of biotin-labeled tau in the basolateral compartment, 
and dQ/dt is the amount of biotin-labeled tau appearing 
in the apical compartment in the given time period [3].
Statistical analysis
Randomization and blinding procedures were employed. 
Quantitative data were plotted as mean ± standard devia-
tion. Statistical analysis was performed using GraphPad 
Prism 8.0 (GraphPad Software, Inc). The Shapiro–Wilk 
test was completed to assess normality. Tau uptake was 
evaluated for significance by ANOVA and the Bonferroni 
post hoc test with multiple comparisons. Tau elimina-
tion, as well as caveolin-1 and Mfsd2a expression were 
evaluated for significance as determined by two-way 
ANOVA Bonferroni post hoc test with multiple com-
parisons. For comparisons between two groups including 
tau transcytosis, angiopoietin secretion and stimulation 
studies, statistical significance was analyzed using a two-
tailed unpaired Student’s t-test or a Mann–Whitney U 
test. For all analyses, a p value of ≤ 0.05 was considered 
statistically significant.
Results
Tau residence time in the brain
To examine the elimination profile of exogenous tau 
from the brain, we evaluated the timecourse by which 
biotin-labeled tau is eliminated from the brain follow-
ing intracranial injection. The half-life of exogenous 
biotin-labeled tau residing in the brain was 41  min 
(Fig. 1A), while the half-life of 10 kDa LyD, which does 
not readily cross the BBB, was nearly 3-times greater 
(114  min) (Fig.  1A). Next, the influence of r-mTBI on 
the elimination of exogenous tau species from the brain 
was evaluated after the intracranial injection of biotin-
labeled tau (2  h). A two-way ANOVA evaluating the 
effect of r-mTBI and the tau species on tau residence 
time demonstrated a statistically significant interaction 
effect [F(3,42) = 2.85, p < 0.05]. A significant main effect 
was observed with respect to injury [F(1,42) = 12.23, 
p < 0.01] and the tau species [F(3,42) = 7.18, p < 0.001]. 
Post hoc Bonferroni tests with multiple comparisons 
between r-mTBI and r-sham revealed a significant 
increase (p < 0.001) in monomeric tau residence in 
r-mTBI (2.62 ± 1.37) compared to r-sham (0.95 ± 0.59) 
(Fig. 1B). While the aggregate enriched species showed 
a twofold elevation in biotin-labeled tau residence 
time in the brain post-injury (1.25 ± 0.72) compared 
to r-sham (0.54 ± 0.20), this value did not reach sta-
tistical significance (p = 0.20) (Fig.  1B). Furthermore, 
additional post hoc Bonferroni tests with multiple 
comparisons evaluated each of the biotin-labeled tau 
species under r-mTBI conditions. There was no sig-
nificant difference between the amount of exogenous 
monomeric and aggregated enriched species residing 
in the brain in the r-sham mice. In the r-mTBI mice, 
there was a significant (p < 0.001) decrease in the resi-
dence of seed competent tau (0.66 + 0.35) compared to 
the amount of exogenous monomeric tau (2.62 ± 1.37) 
(Fig.  1B). Similarly, a significant decrease (p < 0.01) in 
the residence of aggregate enriched tau (1.25 ± 0.72), 
relative to exogenous monomeric tau (2.62 ± 1.37) was 
observed (Fig.  1B). Of note, no statistically significant 
difference in the amount of dextran residing in the 
brain was observed between the r-mTBI and r-sham 
groups for any of the biotin-labeled tau species, indi-
cating the effects of r-mTBI on tau elimination from the 
brain were not due to alterations in BBB integrity (data 
not shown). To characterize tau conformation status, 
MC1 immunoreactivity was elevated in seed competent 
and aggregate enriched biotin-labeled tau compared to 
monomeric biotin-labeled tau (Fig.  1C, D). The hepa-
rin-induced aggregated tau demonstrated substantial 
activity in the ThS assay, while biotin-labeled mono-
meric tau showed minimal activity, near the assay limit 
of detection (Fig. 1E).
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Tau uptake and caveolin‑1 inhibition ex vivo
Our previous work showed reduced cerebrovascu-
lar tau uptake coinciding with diminished caveolin-1 
expression following r-mTBI (12  months post-injury) 
[45]. To further investigate the interaction between cer-
ebrovascular caveolin-1 and extracellular tau, freshly 
isolated cerebrovessels from naïve mice were treated 
with methyl-β-cyclodextrin, a known modulator of 
caveolin-1 [28, 49], prior to exposure to unlabeled mon-
omeric tau. A one-way ANOVA revealed a statistically 
significant treatment effect [F(2,12) = 78.21, p < 0.0001, 
n = 5] on cerebrovascular tau uptake (Fig. 2A). Post hoc 
Bonferroni tests with multiple comparisons revealed 
a significant decrease (p < 0.0001) in tau uptake for 
both 1  mM MβCD (227.8 ± 59.83) and 10  mM MβCD 
(68.31 ± 43.23) when compared to untreated cerebro-
vascular tau uptake (549.8 ± 78.05).
Fig. 1 Effect of r-mTBI on the elimination of exogenous tau species from the brain. A The time course of tau elimination from the brain was 
established by examining biotin-labeled tau (n = 6) and 10 kDa LyD (n = 5) levels in the brain at various time points following intracranial injection 
into naïve wild-type mice (9 months of age). Biotin-labeled tau content was analyzed using an ELISA and LyD was analyzed via fluorescence. 
The half-life for both biotin-labeled tau and LyD were determined using nonlinear regression and a one phase decay fit. B Following intracortical 
injection in r-sham (n = 5–8) and r-mTBI mice (n = 4–8) (12 months post-injury), the amount of exogenous biotin-labeled tau species residing in 
the brain was determined at 2 h post-injection. For each injection, biotin-labeled tau was co-injected with LyD. Biotin-labeled tau content was 
analyzed using an ELISA while LyD was analyzed via fluorescence. Values represent mean ± SD (n = 4–8) and are expressed as pg of tau per μg 
of LyD. **P < 0.01, ***P < 0.001 as compared to r-sham as determined by a two-way ANOVA and Bonferroni post-hoc test. C–E In characterizing 
each tau species, biotin-labeled tau (4.35 µM) was incubated with heparin (1 µM) for 6 h at 37 °C to induce aggregation. The aggregates were 
separated using a 100 kDa molecular weight cutoff filter into aggregate enriched (tau > 100 kDa) or seed competent (tau < 100 kDa) fractions. C 
The conformational status of the seed competent (50 ng/ml) and aggregate enriched (50 ng/ml) biotin-labeled tau fractions were compared to 
monomeric (50 ng/ml) biotin-labeled tau via dot blot using an MC1 antibody. D Quantitative analysis of MC1 immunoreactivity in the dot blot. E 
Heparin-induced in vitro aggregation of monomeric biotin-labeled tau (4.35 µM) was assessed using the indicator dye ThS. ThS fluorescence was 
measured in the presence of monomeric biotin-labeled tau (4.35 µM) immediately after the addition of heparin (1 µM) or vehicle (0 h), and again 
after 6 h. Values represent the change in ThS fluorescence (excitation 450 nm, emission 510 nm) over the 6 h period
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Tau transcytosis across an in vitro BBB model
To more specifically investigate the mechanism by which 
tau is eliminated from the brain, we examined tau tran-
sit across an in vitro model of the BBB. In comparing the 
basolateral-to-apical BBB transit of each biotin-labeled 
tau species, there were no differences in the apparent 
permeability of each biotin-labeled tau species across 
the BBB model under control conditions. Pre-treatment 
with MβCD resulted in a significant decrease (unpaired 
t-Test, t(4) = 4.830, p < 0.01, n = 3) in the BBB transcyto-
sis of monomeric tau (4.75 ± 0.81) compared to untreated 
monomeric tau transcytosis (28.10 ± 8.34) (Fig.  2B). 
Similarly, pre-treatment with MβCD resulted in a sig-
nificant decrease (unpaired t-Test, t(4) = 3.028, p < 0.05, 
n = 3) in aggregate enriched tau transcytosis (7.30 ± 1.48) 
compared to untreated aggregate enriched tau transcy-
tosis (40.97 ± 19.20) (Fig.  2B). Notably, the individual 
biotin-labeled tau species did not appear to impact BBB 
integrity as dextran permeability across the BBB model 
was not different between the biotin-labeled tau spe-
cies. The percentage of dextran crossing the BBB model 
over the 60 min period was 0.90 ± 0.09% for monomeric 
tau and 0.88 ± 0.1% for aggregate enriched tau. Likewise, 
treatment with MβCD had no effect on dextran BBB per-
meability compared to control conditions. The percent-
age of dextran crossing the BBB model over the 60 min 
period was 0.89 ± 0.04% for control and 0.84 ± 0.03% for 
MβCD.
Cerebrovascular expression of caveolin‑1 and Mfsd2a 
in r‑mTBI animals
As Mfsd2a has been shown to regulate caveolin-1 
expression, Mfsd2a and caveolin-1 levels were exam-
ined in isolated cerebrovessels from r-sham and 
r-mTBI animals. A two-way ANOVA was conducted 
that examined the effects of r-mTBI and time on cer-
ebrovascular caveolin-1 expression which revealed 
a statistically significant interaction [F(2,38) = 24.37, 
p < 0.0001] on caveolin-1 expression. A signifi-
cant main effect was observed with respect to time 
[F(2,38) = 30.00, p < 0.001], but there was no signifi-
cant main effect with respect to injury [F(1,38) = 1.496, 
p = 0.229]. Post hoc Bonferroni tests with multiple 
comparisons between r-sham and r-mTBI were con-
ducted to evaluate whether r-mTBI could influence 
the expression of cerebrovascular caveolin-1 compared 
Fig. 2 Effect of MβCD on tau transcytosis across an in vitro model of the BBB. A Freshly isolated cerebrovessels from naïve wild-type mice 
(9 months old) were pretreated with various concentrations of the caveolin inhibitor MβCD (0, 1 mM, 10 mM) for 30 min at 37 °C, before being 
exposed to recombinant human tau (5 ng/ml) for 1 h at 37 °C. Lysates were analyzed for tau content using an ELISA and normalized total protein 
using the BCA assay. Values represent mean ± SD (n = 5) and are expressed as pg of tau per mg of total protein. ****P < 0.0001 compared to vehicle 
as determined by one-way ANOVA and Bonferroni post-hoc test. B MβCD (10 mM) was exposed to the basolateral compartment of the in vitro 
BBB model for 30 min at 37 °C. Following the pretreatment with MβCD, biotin-labeled monomeric or aggregate enriched biotin-labeled tau was 
added alongside the known paracellular marker 10 kDa LyD to the basolateral compartment of the in vitro BBB model. Samples were collected from 
the apical compartment at 0, 30, and 60 min to determine the permeability of biotin-labeled tau and LyD across the BBB model. Values represent 
mean ± SD (n = 3) and are expressed as the apparent permeability coefficient (Papp). *P < 0.05, **P < 0.01 compared to each respective tau species 
with vehicle as determined by unpaired t-Test
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to r-sham animals at each time point. This revealed 
a significant increase (p < 0.001) in cerebrovascular 
caveolin-1 in r-mTBI animals (2055 ± 457.7) com-
pared to r-sham animals (905.7 ± 298.3) at 24  h post 
injury (Fig. 3A). Alternatively, at 3 months post-injury, 
r-mTBI cerebrovessels (350.7 ± 178.3) showed a signif-
icant (p < 0.05) reduction in caveolin-1 (twofold) rela-
tive to r-sham animals (800.0 ± 248.0), and a similar 
significant (p < 0.05) reduction was seen at 6  months 
in r-mTBI cerebrovessels (457.6 ± 209.2) compared 
to r-sham (816.7 ± 340.7) (Fig.  3A). With respect to 
Mfsd2a, a two-way ANOVA evaluating the influence 
of r-mTBI and time post injury on Mfsd2a expres-
sion revealed a significant interaction [F(2,38) = 7.482, 
p < 0.01] and a significant main effect with respect to 
time [F(2,38) = 4.718, p < 0.05], but no significant main 
effect with respect to injury [F(1,38) = 0.001, p = 0.92]. 
Post hoc Bonferroni tests with multiple comparisons 
between r-mTBI and sham revealed that at 24  h post 
injury, there was a significant decrease (p < 0.05) in cer-
ebrovascular Mfsd2a in r-mTBI animals (268.9 ± 64.2) 
compared to sham animals (440.7 + 116.7) (Fig.  3B). 
At 3  months post injury, there was no significant dif-
ference (p = 0.39) between r-mTBI (291.0 ± 77.0) and 
r-sham (245.6 ± 59.9). However, at 6  months post 
injury there was a significant increase (p < 0.01) in cer-
ebrovascular Mfsd2a in r-mTBI animals (434.9 ± 138.8) 
compared to r-sham (299.0 ± 70.9).
Ang‑1/Ang‑2 secretion from r‑mTBI cerebrovessels ex vivo
Prior reporting has indicated the growth factor Ang-1, 
which is primarily secreted by vascular mural cells, was 
elevated in the acute stages after TBI [22] and associated 
with diminished caveolin-1 expression [41]. However, 
the influence of Ang-1 on Mfsd2a and caveolin-1 expres-
sion in the chronic stages post-injury has yet to be inves-
tigated. Administration of Ang-1 to HBMECs in  vitro 
over 24 h lead to a significant increase in levels of Mfsd2a 
(4.12 ± 0.55) compared to untreated cells (2.84 ± 0.57) 
(unpaired t-Test, t(6) = 3.247, p < 0.05, n = 4) (Fig.  4A). 
At 6  months post injury, a Mann–Whitney test indi-
cated that secreted Ang-1 levels from isolated r-mTBI 
cerebrovessels (Mdn = 2080) were significantly higher 
than r-sham (Mdn = 1206) over 72  h (U = 2, p < 0.05, 
n = 5) (Fig. 4B), while there was no significant difference 
in Ang-2 secretion between r-mTBI (Mdn = 1337) and 
r-sham (Mdn = 1731) (Fig. 4B) (U = 11, p = 0.841, n = 5).
Discussion
As pathological tau propagation has been observed in the 
chronic stages of TBI and other neurodegenerative dis-
eases, we explored potential mechanisms responsible for 
the elimination of extracellular tau from the brain and the 
influence of head trauma on these processes. Our recent 
work demonstrated an interaction between extracellular 
tau and brain vascular mural cells (pericytes and smooth 
muscle cells) and showed a progressive decrease in cer-
ebrovascular tau uptake up to 12  months post-injury in 
Fig. 3 Effect of r-mTBI on caveolin-1 and Mfsd2a levels in freshly isolated cerebrovessels from r-mTBI hTau mice (24 h, 3 months, 6 months post-last 
injury). Lysates were analyzed for A caveolin-1 and B Mfsd2a by ELISA and normalized to total protein using the BCA assay. Values represent 
mean ± SD (24 h n = 4, 3 month n = 7, 6 month n = 11) and are expressed as pg of caveolin-1 or ng Mfsd2a per mg total protein. *P < 0.05, 
**P < 0.01, ****P < 0.0001 compared to each respective r-sham as determined by two-way ANOVA and Bonferroni’s multiple comparisons test
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our mouse r-mTBI model [45]. The reduced cerebro-
vascular tau uptake following r-mTBI coincided with a 
significant decrease in caveolin-1 levels in r-mTBI cer-
ebrovessels compared to r-sham animals at 12  months 
post-injury [45]. The present studies continued this line 
of investigation to determine the mechanisms driving 
cerebrovascular tau elimination and the potential impact 
of head trauma on these processes.
The clearance of extracellular tau from the ISF has 
not been extensively characterized, though it appears 
that extracellular tau can readily enter the plasma as 
increases in ISF tau due to neuronal injury are reflected 
in the plasma shortly after injury [61]. After injection into 
the ISF, tau relocates the perivascular space within and 
around arteriole walls within minutes, and though it is 
not cleared as efficiently as Aβ, recent evidence suggests 
they share common routes of cerebrovascular elimination 
[43]. It was determined that the half-life of tau injected 
into the cisterna magma was less than 2 h and the exog-
enous tau was detectable in the plasma within minutes 
of the injection [61]. In line with these studies, our work 
found the half-life of exogenous tau was approximately 
41 min in the brain following intracranial injection. For 
context, we also injected a 10 kDa dextran marker (LyD), 
that is not readily eliminated from the brain and does not 
cross the BBB [42], and found the half-life of LyD in the 
brain was 4-times the value we observed for exogenous 
tau (164 min vs. 41 min). Prior reporting has indicated a 
significantly longer half-life for tau in the brain, 11 days 
in mice [60] and 20 days in humans [52]. However, it is 
important to note these values encompassed the entire 
life cycle of tau, from neuronal synthesis and cellular 
secretion to elimination, whereas the half-life value for 
tau in the present study only reflects elimination from the 
brain. Thus, based on the elimination profile of tau from 
the brain in our studies, we used a 2-h post-injection 
time-point to examine the influence of head trauma on 
tau residence in the brain.
The amount of exogenous monomeric tau residing in 
the brain was greater in the r-mTBI animals compared 
to r-sham, indicating tau elimination from the brain 
was reduced following head trauma. Interestingly, the 
monomeric tau residing in the r-mTBI brain was greater 
than that observed for the seed competent and aggre-
gate enriched tau species. While studies evaluating the 
interactions of various tau species with brain endothelia 
are lacking, earlier work suggested tau aggregates, but 
not monomeric tau, efficiently bind to neurons and are 
Fig. 4 Influence of r-mTBI on cerebrovascular angiopoietin secretion. A Mfsd2a expression in HBMEC following treatment with Ang-1 (2.5 ng/ml) 
for 24 h at 37 °C. Ang-1 expression was quantified by ELISA and normalized to total protein using the BCA assay. Values represent mean ± SD (n = 4) 
and are expressed as ng Mfsd2a per μg of total protein. *P < 0.05 compared to vehicle as determined by unpaired t-Test. B Secretion of Ang-1 and 
Ang-2 from fresh cerebrovessels isolated from r-sham and r-mTBI hTau mice. Following 72 h of incubation at 37 °C, the cerebrovascular extracellular 
media was probed for Ang-1 and Ang-2 using an ELISA and normalized to total protein using the BCA assay. Values represent mean ± SD (n = 5) and 
are expressed as pg of Ang-1 or Ang-2 per mg total protein. *P < 0.05 compared to each respective r-sham as determined by a Mann–Whitney U 
test
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internalized using bulk endocytosis [58]. A more recent 
report found that both monomeric and aggregated tau 
can be internalized with similar efficiency in neurons, but 
may do so through distinct pathways [18]. Solute inter-
nalization and trafficking at the BBB are both regulated 
by ligand binding avidity and particle size [56]. which 
differ between tau aggregates and monomers, and may 
describe any differences in endothelial internalizing and 
trafficking amongst various tau species. Clearly, further 
work is necessary to understand the regulatory mecha-
nisms governing cerebrovascular tau elimination and the 
potential influence of head trauma on these processes.
There are several pathways through which tau can be 
eliminated from the brain including, but not limited to, 
(1) degradation, (2) perivascular drainage, and (3) BBB 
transcytosis. While tau has been shown to be degraded 
in the brain, these processes generally occur over a longer 
period of time (> 12 h) [12, 14] than the 2–3 h elimination 
time-frame in our experimental paradigm, so degradation 
does not appear to be a primary driver of extracellular 
tau elimination from the brain in our particular studies. 
Previous work found that paravascular tau clearance was 
reduced by approximately 60% following TBI and was 
associated with phospho-tau pathology and neurodegen-
eration [26]. The authors noted that if there were a tau 
efflux mechanism, at the BBB for example, their theory of 
convective bulk flow may contribute to tau ISF clearance 
by effectively distributing tau along the vascular bed for 
more efficient transcytosis [26]. That said, there has been 
little investigation into the transit of tau across the BBB. 
Banks and colleagues found that full-length tau and vari-
ous truncated tau proteins readily crossed the BBB bidi-
rectionally and entered the blood following injection into 
the brain [8], consistent with our intracranial tau injec-
tion studies. In line with these BBB findings, our studies 
employed a recently described indirect co-culture BBB 
model [30] consisting of brain endothelia and pericytes, 
and found the BBB transit of each tau species was greater 
than that observed for LyD (basolateral-to-apical). In 
comparing the tau species, the aggregate enriched tau 
showed increased BBB transcytosis compared to mono-
meric tau, potentially explaining the enhanced elimina-
tion of these species in the tau residence studies above.
As indicated above, our prior work showed a correla-
tion between tau uptake and caveolin-1 expression in 
isolated cerebrovessels, suggesting tau endocytosis in 
these cells may be mediated by caveolin-1. In the pre-
sent studies, modulating caveolae with MβCD resulted 
in a significant decrease in cerebrovascular tau uptake 
and dramatically reduced the BBB transit of both tau 
monomers and aggregate enriched species of tau. Of 
note, while several studies have demonstrated MβCD 
to be an effective disruptor of caveolae and caveolin-1 
[28, 49] we cannot rule out any nonspecific effects of 
MβCD (i.e., other than caveolin-1) on cerebrovascu-
lar tau transit. That said, it was previously reported that 
mice with reduced caveolin-1 brain expression showed 
elevated levels of total and phosphorylated tau in the 
hippocampus compared to wild-type animals [10, 25]. 
Collectively these findings indicate tau proteins can 
be eliminated across the BBB, which may be mediated 
through caveolin-1.
There is a dearth of research into the long-term effects 
of TBI on caveolin-1, particularly in the context of repeti-
tive injury, but our previous studies found a significant 
downregulation in cerebrovascular caveolin-1 levels at 
12  months post-injury in a mouse r-mTBI model [45]. 
Looking more acutely, our current results demonstrate 
an upregulation of caveolin-1 expression at 24  h post-
injury, consistent with prior reporting of increased cave-
olin-1 expression within the neurovascular unit during 
the same 24-h period following TBI in juvenile rats [6]. 
However, in this rat TBI model, the increased expression 
appeared to be transient, as caveolin-1 levels returned to 
baseline 3 days after the brain injury [6]. The acute upreg-
ulation of caveolin-1 post-injury could explain the tran-
sient increase in plasma tau levels observed immediately 
following sports-related concussive injury [21]. In the 
more chronic phase post-injury, we observed decreased 
expression of caveolin-1 following r-mTBI at 3 and 
6  months post-injury compared to r-sham, consistent 
with what was observed at 12  months post-injury [45]. 
It has been proposed that the upregulation of caveolin-1 
acutely following cerebral insult is meant to facilitate 
vascular repair by promoting angiogenesis and stabiliz-
ing tight junction and efflux proteins (e.g., claudin-5 and 
P-glycoprotein) [6]. However, as observed in the present 
studies, the chronic downregulation of caveolin-1 after 
r-mTBI could hamper waste elimination from the brain, 
leading to the accumulation of extracellular solutes such 
as tau, as demonstrated in other animal models where 
caveolin-1 is chronically diminished in the brain [10, 25].
A primary regulator of caveolae-mediated transcyto-
sis in brain endothelia is the lipid transporter Mfsd2a, 
which inhibits caveolae vesicle formation by modulating 
the lipid composition of brain endothelial membranes to 
suppress transcytosis [2] and regulate BBB integrity [62]. 
As a result, transcytosis via caveolin-1 is inversely related 
to Mfsd2a expression in the BBB. Correspondingly, we 
found cerebrovascular Mfsd2a levels were decreased at 
24 h following r-mTBI, while caveolin-1 levels were sig-
nificantly increased compared to r-sham animals dur-
ing this time frame. Along these lines, prior reporting 
showed Mfsd2a levels were significantly decreased in 
the acute stage after surgical brain injury [16, 17] and, 
interestingly, Mfsd2a upregulation was found to reverse 
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BBB disruption by altering caveolae-based transport, 
providing neuroprotection following injury-induced 
sub-arachnoid hemorrhage [63]. In terms of the chronic 
phase post-injury, there is a lack of evidence regarding 
the response of cerebrovascular Mfsd2a to head trauma. 
That said, while Mfsd2a levels are generally decreased 
in acute conditions such as intracerebral hemorrhage, 
Mfsd2a has been shown to be largely upregulated in 
more chronic disorders such as chronic liver injury 
and inflammatory bowel disease [16]. In line with these 
studies, we observed a progressive increase in cerebro-
vascular Mfsd2a levels in the chronic phase post-injury 
(6 months following r-mTBI), though more work is nec-
essary to understand the consequence of altered Mfsd2a 
expression in the brain following head trauma, especially 
in the more chronic stages post-injury.
Mfsd2a expression in brain endothelia has been shown 
to be directly regulated by cerebrovascular mural cells 
[9]. Dysfunctional endothelial transcytosis after injury 
appears to be primarily driven by altered pericyte cross-
talk with endothelial cells [54]. To this point, the mecha-
nism by which mural cells regulate endothelial expression 
of Mfsd2a and caveolin-1 is unclear, though evidence 
suggests the signaling factors angiopoietin-1 (Ang-1) 
and angiopoietin-2 (Ang-2) may play a role. Ang-1 is 
predominantly expressed and constitutively released by 
vascular mural cells [20, 55]. to facilitate vessel assem-
bly and stability and is a critical survival factor in pre-
venting endothelial cell death [29]. In addition, Ang-1 is 
known to activate the signaling pathway that downregu-
lates plasmalemma vesicle-associated protein expression, 
which is also responsible for caveolin formation [31]. 
Alternatively, Ang-2 is almost exclusively secreted by 
endothelial cells and functions as a negative regulator of 
the Ang-1 pathway in order to modulate vessel matura-
tion [19, 24]. The impact of Ang-1 on caveolin-1 expres-
sion was demonstrated recently in rats, where increased 
caveolin-1 levels following acute brain trauma were 
reversed with Ang-1 treatment [41]. In a similar manner, 
our studies found that treatment with Ang-1 significantly 
increased Mfsd2a expression in human brain endothe-
lial cells. Altogether, alterations in the secretion of 
Ang-1 (from brain vascular mural cells) or Ang-2 (from 
brain endothelia) following brain injury could influence 
endothelial transcytosis by modulating the Mfsd2a/cave-
olin-1 pathway.
Previous reports have shown vascular mural cells 
upregulate Ang-1 in response to insults such as hypoxic 
conditions, while Ang-2 levels were largely decreased 
or unchanged [15, 48]. With respect to TBI, prior stud-
ies have reported a progressive decrease in Ang-1 levels 
in the brain [50] and capillaries [15] over the first 48  h 
following brain injury. At later stages of brain injury, 
pericytes become reactive and secrete angiogenic growth 
factors including Ang-1 to mediate endothelial cell activ-
ity and vascular integrity [51]. There has been a lack of 
work examining Ang-2 levels following TBI, however 
Ang-2 levels were found to be increased acutely in the 
brain following subarachnoid hemorrhage [23] and cold-
injury [44], but the chronic status of Ang-2 in the brain 
following cerebral insult is currently unknown. That said, 
as the time increases post-injury (days and weeks fol-
lowing head trauma), several studies have reported an 
increase in Ang-1 levels in the brain [11, 50] and serum 
[22]. Our studies coincide with these findings as freshly 
isolated cerebrovessels from r-mTBI animals (6  months 
post-injury) secreted significantly higher levels of Ang-1 
compared to r-sham animals, while cerebrovascular 
Ang-2 secretion was unchanged between the r-mTBI and 
r-sham animals.
Conclusions
These studies indicate tau elimination from the brain is 
diminished following r-mTBI, which may be the result 
of decreased caveolin-1-mediated tau transit across the 
BBB. Our prior work showed mural cell dysfunction and 
decreased cerebrovascular tau uptake coinciding with 
reduced caveolin-1 expression in the chronic phase fol-
lowing r-mTBI. The current studies suggest the changes 
in caveolin-1 post-injury may be due to alterations in 
Mfsd2a expression in the BBB in response to increased 
Ang-1 secretion from dysfunctional mural cells in the 
aftermath of brain injury. Taken together, aberrant mural 
cell function following r-mTBI diminishes caveolae-
mediated tau elimination across the BBB, which may 
describe the chronic accumulation of tau deposits typi-
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